Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2020 07:57 ET | Source: Aptinyx Inc.

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
June 16, 2020 08:37 ET | Source: Aptinyx Inc.

Aptinyx to Present at Upcoming Virtual Investor Conferences

EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
May 14, 2020 16:03 ET | Source: Aptinyx Inc.

Aptinyx Reports First Quarter 2020 Financial Results and Highlights

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
April 30, 2020 08:47 ET | Source: Aptinyx Inc.

Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020

EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
March 30, 2020 16:01 ET | Source: Aptinyx Inc.

Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
March 18, 2020 16:01 ET | Source: Aptinyx Inc.

Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020

EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
February 19, 2020 08:37 ET | Source: Aptinyx Inc.

Aptinyx to Present at Upcoming Investor Conferences

EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
January 30, 2020 07:07 ET | Source: Aptinyx Inc.

Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease

EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
January 14, 2020 16:01 ET | Source: Aptinyx Inc.

Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option

EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
January 10, 2020 09:00 ET | Source: Aptinyx Inc.

Aptinyx Announces Pricing of Public Offering of Common Stock

EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

Next Page keyboard_arrow_right